Skip to main content
. Author manuscript; available in PMC: 2016 Mar 14.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 Jan 22;21(5):866–872. doi: 10.1016/j.bbmt.2015.01.017

Table 3. Patient Characteristics by Monosomal Karyotype and IPSS at Diagnosis.

IPSS R-IPSS
Variable No MK MK P-
value
Good Intermediate Poor P-
value
Good/
Very Good
Intermediate Poor Very Poor P-
value
Age of Patient < 50 26 (31%) 13 (36%) 0.82 6 (17%) 14 (50%) 20 (35%) 0.03 6 (17%) 11 (46%) 15 (47%) 8 (28%) 0.04
50-60 32 (39%) 14 (39%) 13 (37%) 8 (29%) 25 (43%) 13 (36%) 8 (33%) 11 (34%) 14 (48%)
>60 25 (30%) 9 (25%) 16 (46%) 6 (21%) 13 (22%) 17 (47%) 5 (21%) 6 (19%) 7 (24%)
Age (Years) Median (range) 55 (19-72) 52 (19-69) 0.88 58 (27-72) 52 (21-69) 52 (19-72) 0.11 59 (27-72) 53 (28-69) 51 (19-72) 53 (22-69) 0.17
Patient Gender Male 55 (66%) 24 (67%) 0.97 23 (66%) 17 (61%) 40 (69%) 0.75 23 (64%) 16 (67%) 23 (72%) 18 (62%) 0.86
KPS <90 19 (23%) 5 (14%) 0.29 6 (17%) 7 (25%) 11 (19%) 0.73 7 (19%) 6 (25%) 7 (22%) 4 (14%) 0.80
90/100 64 (77%) 30 (83%) 29 (83%) 21 (75%) 46 (79%) 29 (81%) 18 (75%) 25 (78%) 24 (86%)
Recipient CMV Positive 46 (55%) 19 (53%) 19 (54%) 18 (64%) 28 (48%) 0.38 20 (56%) 16 (67%) 14 (44%) 15 (52%) 0.39
Donor Type RD/URD Match 42 (51%) 23 (64%) 0.44 17 (49%) 14 (50%) 35 (60%) 0.19 18 (50%) 12 (50%) 16 (50%) 20 (69%) 0.22
RD/URD MM 6 (7%) 2 (6%) 2 (6%) 4 (14%) 2 (3%) 2 (6%) 4 (17%) 1 (3%) 1 (3%)
UCB 5+6/6 19 (23%) 4 (11%) 11 (31%) 3 (11%) 10 (17%) 11 (31%) 3 (13%) 6 (19%) 4 (14%)
UCB 4/6 16 (19%) 7 (19%) 5 (14%) 7 (25%) 11 (19%) 5 (14%) 5 (21%) 9 (28%) 4 (14%)
Conditioning MA 32 (39%) 13 (36%) 0.97 11 (31%) 11 (39%) 24 (41%) 0.78 11 (31%) 8 (33%) 16 (50%) 11 (38%) 0.61
RIC: w/ ATG 35 (42%) 16 (44%) 17 (49%) 10 (36%) 24 (41%) 18 (50%) 9 (38%) 11 (34%) 13 (45%)
RIC: w/o ATG 16 (19%) 7 (19%) 7 (20%) 7 (25%) 10 (17%) 7 (19%) 7 (29%) 5 (16%) 5 (17%)
GvHD Prophylaxis CSA/MMF 52 (63%) 21 (58%) 0.57 23 (66%) 18 (64%) 32 (55%) 0.77 24 (67%) 17 (71%) 17 (53%) 15 (52%) 0.49
CSA containing 21 (25%) 8 (22%) 8 (23%) 7 (25%) 15 (26%) 8 (22%) 4 (17%) 11 (34%) 7 (24%)
Other 10 (12%) 7 (19%) 4 (11%) 3 (11%) 11 (19%) 4 (11%) 3 (13%) 4 (13%) 7 (24%)
Diagnosis MDS-NOS 12 (15%) 10 (28%) 0.30 6 (17%) 5 (18%) 13 (22%) 0.04 6 (17%) 5 (21%) 13 (21%) 5 (17%) 0.05
MDS - RA 5 (6%) 0 1 (3%) 2 (7%) 2 (3%) 1 (3%) 3 (13%) 1 (3%) 0
MDS - RAEB-1 21 (25%) 11 (31%) 7 (20%) 6 (21%) 19 (33%) 18 (50%) 4 (17%) 2 (6%) 6 (21%)
MDS - RAEB-2 25 (30%) 5 (14%) 18 (51%) 5 (18%) 7 (12%) 2 (6%) 0 1 (3%) 1(3%)
MDS - RARS 3 (4%) 1 (3%) 1 (3%) 1 (4%) 2 (3%) 1 (3%) 5 (21%) 7 (22%) 8 (28%)
MDS - RCMD 13 (16%) 8 (22%) 1 (3%) 7 (25%) 13 (22%) 1 (3%) 2 (8%) 1 (3%) 1 (3%)
RCMD - RS 4 (5%) 1 (3%) 1 (3%) 2 (7%) 2 (3%) 7 (19%) 5 (21%) 12 (38%) 8 (28%)
Therapy-related MDS yes 13 (16%) 13 (36%) 0.01 16 (46%) 5 (18%) 6 (10%) <0.01 1 (3%) 4 (17%) 13 (41%) 19 (68%) <0.01
Blast at TX <=2% 46 (55%) 27 (75%) 0.07 21 (60%) 15 (54%) 38 (66%) 0.53 22 (61%) 13 (54%) 18 (56%) 21 (72%) 0.61
>2-<5% 25 (30%) 4 (11%) 11 (31%) 8 (29%) 11 (19%) 11 (31%) 7 (29%) 8 (25%) 4 (14%)
5-10% 12 (15%) 5 (14%) 3 (9%) 5 (18%) 9 (16%) 3 (8%) 4 (17%) 6 (19%) 4 (14%)
Chemotherapy No 43 (52%) 16 (44%) 0.46 34 (97%) 23 (85%) 35 (61%) <0.01 35 (97%) 23 (96%) 24 (80%) 1 (3%) <0.01
Yes 40 (48%) 20 (56%) 1 (3%) 4 (15%) 22 (39%) 1 (3%) 1 (4%) 6 (20%) 28 (97%)
MK No 34 (97%) 27 (96%) 22 (39%) <0.01 6.7 (1-372) 7.4 (2-63) 5.4 (2-73) 5.2 (2-38) 0.06
Yes 1 (3%) 1 (4%) 34 (61%) 1 (3%) 4 (17%) 13 (41%) 19 (68%) <0.01
Months to AlloHCT Median (range) 6.7 (1-372) 5.3 (2-39) 0.14 6.3 (1-77) 10.4 (2-81) 5.3 (2-372) 0.58 22 (61%) 13 (54%) 18 (56%) 21 (72%) 0.61